Want to see PRPO full AI Analyst Report?
PRPO Stock Chart & Stats
$23.09
$0.30(5.08%)
At close: 4:00 PM EST
$23.09
$0.30(5.08%)
Day’s Range― - ―
52-Week Range$13.02 - $33.63
Previous CloseN/A
Volume11.00
Average Volume (3M)19.92K
Market Cap
$44.04M
Enterprise Value$45.47
Total Cash (Recent Filing)$2.60M
Total Debt (Recent Filing)$3.49M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding1,787,372
10 Day Avg. Volume16,445
30 Day Avg. Volume19,918
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)2.53
Price to Sales (P/S)1.53
P/FCF Ratio102.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.4
Revenue Forecast (FY)$80.26M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth And Commercial PipelineRevenue growth has accelerated materially (Q1 +30% YoY; TTM up) while management reports a ~$10M annualized commercial pipeline and new distributor relationships. That combination supports durable top-line expansion if conversion and onboarding progress, underpinning multi-quarter organic growth.
Improving Cash Generation And MarginsThe company shifted from multi-year cash burn to positive operating and free cash flow, alongside materially improved gross and EBITDA margins. Sustained positive cash generation improves financial flexibility, funds sales investments, and reduces refinancing risk over the next several quarters.
Manageable Leverage And Scalable Lab CapacityLow leverage provides balance sheet flexibility for a small diagnostics operator. Meaningful unused lab capacity lets the company scale volumes and spread fixed costs without immediate heavy CapEx, supporting durable margin expansion as revenue grows.
Bears Say
Incomplete And Inconsistent ProfitabilityDespite margin and cash improvements, the company remains roughly break‑even with a small TTM net loss and periodic negative adjusted EBITDA. Continued inconsistent profitability raises execution risk and means the firm must sustain growth and cost control to embed a durable earnings base.
Material Reimbursement ExposureSignificant payor reimbursement changes can quickly erode revenue and margins for lab-based diagnostics. The recent CMS cut produced a measurable write-down, evidencing structural sensitivity to third‑party fee schedules and creating recurring downside risk to revenue predictability.
Onboarding And Operational Execution RiskThe business model depends on converting pipeline via complex customer onboarding. Persistent operational frictions—IT integrations, validations, equipment uptime—can delay revenue recognition, depress near‑term margins, and make scaling outcomes volatile over multiple quarters.
Precipio News
PRPO FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was $13.02 and its highest was $33.63 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is $44.04M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is Aug 04, 2026 which is in 14 days.
How were Precipio Inc’s earnings last quarter?
Precipio Inc released its earnings results on May 14, 2026. The company reported -$0.809 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Overvalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,787,372 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Precipio Inc reported an EPS of -$0.809 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.951%.
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in PRPO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precipio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
PRPO Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $100.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.97%
Trailing 12-Months
Company Description
Precipio Inc
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Technical Analysis
Trinity Biotech
―
DarioHealth
―
BioNano Genomics
―
Intelligent Bio Solutions
―
bioAffinity Technologies, Inc.
―
Ownership Overview
10.89% Insiders
2.28% Mutual Funds
1.91% Other Institutional Investors
81.88% Public Companies and
Individual Investors